mog 35 55 peptide MOG35

mog 35 55 peptide a relapsing-remitting neurological disease with extensive plaque-like demyelination - Mogcfa emulsion MOG35

Mog3555sequence The mog 35 55 peptide is a crucial tool in neuroscience research, particularly for understanding and modeling demyelinating diseases.MOG (35-55), mouse, rat This specific fragment of Myelin Oligodendrocyte Glycoprotein (MOG) is widely utilized to induce experimental autoimmune encephalomyelitis (EAE), a condition that closely mimics the pathological hallmarks of multiple sclerosis (MS) in animal models.Myelin Oligodendrocyte Glycoprotein Peptide Fragment 35 ... By studying the effects of the MOG (35-55) peptide, researchers gain insights into the autoimmune processes that lead to neurological damage and disability.

Understanding the MOG (35-55) Peptide

Myelin Oligodendrocyte Glycoprotein (MOG) is a protein component of the myelin sheath in the central nervous system (CNS). The MOG 35-55 peptide represents a specific sequence within this larger protein, known to be a potent antigen. When introduced into an experimental subject, this peptide can trigger an immune response that targets the body's own myelin, leading to inflammation and demyelinationMOG 35–55 Peptide – Key Epitope in MS Research | p&e. This process is instrumental in creating animal models that replicate key features of human neurological disorders.

Role in Disease Modeling

The primary application of the mog 35 55 peptide is in the induction of Experimental Autoimmune Encephalomyelitis (EAE). This animal model is characterized by:

* Demyelination: The breakdown of the myelin sheath, which insulates nerve fibers, impairs nerve signal transmission.

* Neurological Symptoms: EAE often manifests as a relapsing-remitting neurological disease, with symptoms that can include paralysis and other motor deficits, mirroring the clinical presentation of multiple sclerosis.

* Autoimmune Response: The immune system mistakenly attacks myelin, driven by T cell responses against the MOG peptide.

Researchers use MOG (35-55) to study various aspects of these diseases, including the development of autoantibodies, the role of specific immune cells like T cells, and the efficacy of potential therapeutic interventions.MOG Peptide 35-55Rat, Mouse... Читать далее →. Характеристики реактива. assay. ≥97% (HPLC). storage temp. −20°C ... Все характеристики. Facebook. Twitter.

MOG (35-55) in Multiple Sclerosis Research

Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system. The MOG (35-55) peptide has emerged as a key epitope in MS research because its induction of EAE produces a disease state with extensive plaque-like demyelination, a hallmark pathology of MS. Studies involving this peptide help to elucidate the mechanisms underlying MS pathogenesis, identify potential biomarkers, and test novel treatment strategies aimed at preventing or reversing demyelination and neuroinflammation. While MOG is a known target in some forms of MS, particularly in children, the MOG (35-55) fragment is a well-established tool for *modeling* the disease process in research settings.

Applications and Variations

The mog 35 55 peptide is available in various forms, often specified by species (e.g., human, mouse, rat) and purity levels, typically measured by HPLC. Researchers select specific versions of the peptide based on their experimental design and the animal models they are using. The peptide is commonly used in conjunction with adjuvants and myelin oligodendrocyte glycoprotein (MOG) emulsified forms to ensure a robust immune response. Beyond EAE induction, the peptide can also be employed in T cell assays and for generating anti-MOG antibodies in vitro and in vivo, further aiding in the study of autoimmune responses.

In conclusion, the mog 35 55 peptide is an indispensable reagent for advancing our understanding of demyelinating diseases like multiple sclerosisMyelin Oligodendrocyte Glycoprotein Peptide (35-55) .... Its ability to reliably induce EAE provides a critical platform for investigating disease mechanisms and developing new therapies.

Log In

Sign Up
Reset Password
Subscribe to Newsletter

Join the newsletter to receive news, updates, new products and freebies in your inbox.